首页> 外文期刊>American Journal of Cancer Research >Genetic polymorphisms in oxidative stress-related genes are associated with clinical outcome in patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitors
【24h】

Genetic polymorphisms in oxidative stress-related genes are associated with clinical outcome in patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitors

机译:氧化应激相关基因的遗传多态性与接受酪氨酸激酶抑制剂的晚期非小细胞肺癌患者的临床结局相关

获取原文
           

摘要

Many types of cancer have high antioxidant capacity that effectively scavenges reactive oxygen species and thus protect cancer cells against oxidative damage. The aim of this study was to examine the effect of 20 single nucleotide polymorphisms (SNPs) in 20 oxidative stress-related genes on clinical outcome in 219 patients with advanced non-small cell lung cancer (NSCLC) who were treated with EGFR tyrosine kinase inhibitors (TKIs). We assessed the associations of SNPs with prognosis in all patients as well as stratified by clinical characteristics. Three SNP (rs1695, rs2333227 and rs699512) were significantly associated with overall survival (OS). In a multivariate analysis, rs1695 AA and rs2333227 AG/GG genotypes were identified as independent prognostic factors for poor OS. Stratification analyses revealed that these 3 SNPs remained significantly associated with OS. Furthermore, there was a strong gene-dosage effect of these 3 SNPs on OS that patients with increasing number of unfavorable genotypes had significantly increased death risk. In conclusion, our findings provide the first evidence that genetic variants in oxidative stress-related genes may influence treatment outcome in advanced NSCLC patients receiving EGFR TKIs.
机译:许多类型的癌症具有很高的抗氧化能力,可以有效清除活性氧,从而保护癌细胞免受氧化损伤。这项研究的目的是检查EGFR酪氨酸激酶抑制剂治疗的219例晚期非小细胞肺癌(NSCLC)患者中20个氧化应激相关基因中的20个单核苷酸多态性(SNP)对临床结局的影响(TKI)。我们评估了所有患者中SNP与预后的关系,并按临床特征进行了分层。三个SNP(rs1695,rs2333227和rs699512)与总生存期(OS)显着相关。在多变量分析中,rs1695 AA和rs2333227 AG / GG基因型被确定为OS不良的独立预后因素。分层分析显示,这3个SNP仍与OS显着相关。此外,这3个SNP对OS有很强的基因剂量作用,即越来越多的不利基因型患者死亡风险显着增加。总之,我们的发现提供了第一个证据,即氧化应激相关基因的遗传变异可能影响接受EGFR TKIs的晚期NSCLC患者的治疗结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号